Literature DB >> 22295927

Natural history and imaging prevalence of cavernous malformations in children and young adults.

Wajd N Al-Holou1, Thomas M O'Lynnger, Aditya S Pandey, Joseph J Gemmete, B Gregory Thompson, Karin M Muraszko, Hugh J L Garton, Cormac O Maher.   

Abstract

OBJECT: This study was undertaken to define the age-related prevalence of cavernous malformations (CMs) in children and young adults undergoing intracranial imaging. In addition, the authors aim to clarify the natural history of CMs in young people, especially in those with incidentally discovered lesions.
METHODS: To identify those patients with CMs, the authors retrospectively reviewed the electronic medical records of 14,936 consecutive patients 25 years of age or younger who had undergone brain MR imaging. In patients with a CM, clinical and imaging data were collected. Patients with untreated cavernomas who had more than 6 months of clinical and MR imaging follow-up were included in a natural history analysis. The natural history analysis included 110 CMs in 56 patients with a 3.5-year mean clinical follow-up interval (199 patient-years and 361 cavernoma-years).
RESULTS: In 92 patients (0.6%), 164 CMs were identified. The imaging prevalence of cavernomas increased with advancing age (p = 0.002). Multiple CMs occurred in 28 patients (30%), and 8 patients (9%) had a family history of multiple CMs. Fifty patients (54%) presented with symptoms related to the cavernoma, of whom 30 presented with hemorrhage (33%). Of the 164 cavernomas identified, 103 (63%) were considered incidental, asymptomatic lesions. Larger size was associated with acute symptomatic presentation (p = 0.0001). During the follow-up interval, 6 patients with 8 cavernomas developed 11 symptomatic hemorrhages after initial identification. Five of the patients who had a hemorrhage during the follow-up interval had initially presented with hemorrhage, while only 1 had presented incidentally. The hemorrhage rate for all patients in the natural history group was 1.6% per patient-year and 0.9% per cavernoma-year. The hemorrhage rate was 8.0% per patient-year in the symptomatic group versus 0.2% in the incidental group. Symptomatic hemorrhage after long-term follow-up was associated with initial acute presentation (p = 0.02).
CONCLUSIONS: The imaging prevalence of CM increases with advancing age during childhood. Patients presenting without hemorrhage have a significantly lower risk of bleeding compared with those who present with acute neurological symptoms. Comparing this series of children to prior analyses of CM natural history in adults, the authors' data do not suggest a higher bleeding risk in younger patients.

Entities:  

Mesh:

Year:  2012        PMID: 22295927     DOI: 10.3171/2011.11.PEDS11390

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  34 in total

1.  Prospective Hemorrhage Rates of Cerebral Cavernous Malformations in Children and Adolescents Based on MRI Appearance.

Authors:  O Nikoubashman; F Di Rocco; I Davagnanam; K Mankad; M Zerah; M Wiesmann
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-13       Impact factor: 3.825

Review 2.  Natural history of cavernous malformation: Systematic review and meta-analysis of 25 studies.

Authors:  Shervin Taslimi; Amirhossein Modabbernia; Sepideh Amin-Hanjani; Fred G Barker; R Loch Macdonald
Journal:  Neurology       Date:  2016-04-22       Impact factor: 9.910

Review 3.  Rho kinase as a target for cerebral vascular disorders.

Authors:  Lisa M Bond; James R Sellers; Lisa McKerracher
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

4.  A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease.

Authors:  Lisa McKerracher; Robert Shenkar; Matthew Abbinanti; Ying Cao; Amy Peiper; James K Liao; Rhonda Lightle; Thomas Moore; Nicholas Hobson; Carol Gallione; Joerg Ruschel; Janne Koskimäki; Romuald Girard; Kenneth Rosen; Douglas A Marchuk; Issam A Awad
Journal:  Transl Stroke Res       Date:  2019-08-24       Impact factor: 6.829

5.  B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models.

Authors:  Changbin Shi; Robert Shenkar; Hussein A Zeineddine; Romuald Girard; Maged D Fam; Cecilia Austin; Thomas Moore; Rhonda Lightle; Lingjiao Zhang; Meijing Wu; Ying Cao; Murat Gunel; Angeliki Louvi; Autumn Rorrer; Carol Gallione; Douglas A Marchuk; Issam A Awad
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-16       Impact factor: 4.147

Review 6.  Neuroimaging of Cavernous Malformations.

Authors:  Maxim Mokin; Siviero Agazzi; Lowell Dawson; Christopher T Primiani
Journal:  Curr Pain Headache Rep       Date:  2017-10-13

Review 7.  Cerebral Cavernous Malformations: An Update on Prevalence, Molecular Genetic Analyses, and Genetic Counselling.

Authors:  Stefanie Spiegler; Matthias Rath; Christin Paperlein; Ute Felbor
Journal:  Mol Syndromol       Date:  2018-01-25

8.  Large Vessel Arteriopathy After Cranial Radiation Therapy in Pediatric Brain Tumor Survivors.

Authors:  Matthew Nordstrom; Erin Felton; Katherine Sear; Benita Tamrazi; Joseph Torkildson; Karen Gauvain; Daphne A Haas-Kogan; Josephine Chen; Benedict Del Buono; Anuradha Banerjee; David Samuel; David Saloner; Bing Tian; Erika Roddy; Christopher Hess; Heather Fullerton; Sabine Mueller
Journal:  J Child Neurol       Date:  2018-04       Impact factor: 1.987

9.  Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults: Mayo Clinic Study of Aging.

Authors:  Kelly D Flemming; Jonathan Graff-Radford; Jeremiah Aakre; Kejal Kantarci; Giuseppe Lanzino; Robert D Brown; Michelle M Mielke; Rosebud O Roberts; Walter Kremers; David S Knopman; Ronald C Petersen; Clifford R Jack
Journal:  JAMA Neurol       Date:  2017-07-01       Impact factor: 18.302

10.  Postnatal delayed exacerbation of dural sinus malformation associated with brainstem cavernous malformations: A case report.

Authors:  Katsuhiro Mizutani; Tomoru Miwa; Takenori Akiyama; Tokunori Kanazawa; Hideaki Nagashima; Kei Miyakoshi; Yasunari Niimi; Kazunari Yoshida
Journal:  Interv Neuroradiol       Date:  2017-07-20       Impact factor: 1.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.